Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications

Introduction The endothelial surface layer is covered with abundant proteoglycans, of which syndecans and glycosaminoglycans are major constituents. Recent Findings Among the endothelial glycocalyx (eGC) constituents, syndecan-1 (sdc1) is a main component, and an elevated serum level of sdc1 may ind...

Full description

Saved in:
Bibliographic Details
Published in:Current heart failure reports 2017-04, Vol.14 (2), p.117-126
Main Authors: Kim, Youn-Hyun, Nijst, Petra, Kiefer, Kathryn, Tang, W. H. Wilson
Format: Article
Language:English
Subjects:
Biomarkers - blood
Biomarkers of Heart Failure (W H W Tang and J Grodin
Cardiac Surgery
Cardiology
Cardiovascular Diseases - blood
Endothelium, Vascular - chemistry
Glycocalyx - chemistry
Glycocalyx - metabolism
Heart Failure - blood
Humans
Imaging
Internal Medicine
Medicine
Medicine & Public Health
Myocardial Ischemia - blood
Radiology
Section Editors
Syndecan-1 - blood
Topical Collection on Biomarkers of Heart Failure
Vascular Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The endothelial surface layer is covered with abundant proteoglycans, of which syndecans and glycosaminoglycans are major constituents. Recent Findings Among the endothelial glycocalyx (eGC) constituents, syndecan-1 (sdc1) is a main component, and an elevated serum level of sdc1 may indicate the degradation of eGC. In patients with ischemic heart disease or heart failure, elevation of serum sdc1 has been associated with worsening cardiac and renal function; however, the causal relationship between degradation of eGC and clinical outcomes is unclear. Summary Herein, we review the previous literature on eGC in cardiovascular and noncardiovascular diseases and their clinical implications.
ISSN:1546-9530
1546-9549
DOI:10.1007/s11897-017-0320-5